MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced Douglas J.
Swirsky has been appointed as the Company’s Chief Financial
Officer, effective immediately. Mr. Swirsky is a seasoned financial
leader with over two decades of experience in the healthcare
sector, including as a public company executive at Nasdaq-listed
organizations.
“We are excited to welcome
Douglas to MaxCyte where he brings exceptional financial,
strategic, and operational experience in the life science and
biopharmaceutical sectors, including extensive experience as a
public company CFO,” said Doug Doerfler, President and CEO
of MaxCyte. “His breadth of experience will play a pivotal
role in MaxCyte’s continued growth as an industry leading
cell-engineering company. We look forward to leveraging his deep
finance and industry knowledge as we execute on our strategic and
financial goals.”
Prior to joining MaxCyte, Mr. Swirsky served as
Chief Financial Officer and Treasurer of AavantiBio, Inc. a gene
therapy company, from February 2021 until its acquisition by Solid
Biosciences, Inc. in December 2022, initially joining AavantiBio as
its Interim President and a director in May 2020. Mr. Swirsky’s
experience also includes serving as President, Chief Executive
Officer and a director of Rexahn Pharmaceuticals, Inc. (NASDAQ:
REXN) from 2018 to 2020. Mr. Swirsky served as President, CEO and a
director of GenVec, Inc. (NASDAQ:GNVC), a publicly traded
biotechnology company, a position he held from 2013 through the
sale of the company in 2017. He joined GenVec in 2006 as Chief
Financial Officer.
Prior to GenVec, Mr. Swirsky was a Managing
Director and the Head of Life Sciences Investment Banking at Stifel
Nicolaus and previously held investment banking positions at Morgan
Stanley, UBS, PaineWebber, and Legg Mason. Mr. Swirsky currently
serves as the Chairman of the Board of Cellectar Biosciences, Inc.
(NASDAQ:CLRB), a publicly traded clinical stage biopharmaceutical
company.
Mr. Swirsky is a certified public accountant and
a CFA® charterholder. He received his B.S. in Business
Administration from Boston University and his M.B.A. from the
Kellogg School of Management at Northwestern University.
“I am honored to join MaxCyte’s strong
leadership team during this exciting period of growth at the
Company, and to support our mission to help drive the next
generation of cell-based therapies,” said Douglas
Swirsky. “As CFO, I look forward to leading MaxCyte’s
financial operations to position the Company for continued success,
and to helping create long term shareholder value.”
Ron Holtz, who served as MaxCyte’s CFO from 2005
until September 2020 and again since May 2022, having served as
Chief Accounting Officer during the interim period, will take on
the role of EVP, Administration for the Company.
“It has been an honor serving as part of the
MaxCyte executive team for nearly eighteen years,” said Ron
Holtz. “I welcome Douglas to MaxCyte and look forward to
supporting his success as MaxCyte’s CFO. His exceptional background
and experience will be invaluable to MaxCyte as we move forward
through the next phases of growth.”
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation® technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including but
not limited to, statements regarding the Company’s expected growth
and its execution of its strategic and financial goals. The words
"may," “might,” "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," “expect,” "estimate,"
“seek,” "predict," “future,” "project," "potential," "continue,"
"target" and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, risks associated with the timing of
our customers’ ongoing and planned clinical trials; the adequacy of
our cash resources and availability of financing on commercially
reasonable terms; general market and economic conditions that may
impact investor confidence in the biopharmaceutical industry and
affect the amount of capital such investors provide to our current
and potential partners; and demand for our products. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in our Annual Report on Form
10-K for the year ended December 31, 2022, filed with the
Securities and Exchange Commission on March 15, 2023, as well as in
discussions of potential risks, uncertainties, and other important
factors in the other filings that we make with the Securities and
Exchange Commission from time to time. These documents are
available under the “SEC filings” page of the Investors section of
our website at http://investors.maxcyte.com. Any forward-looking
statements represent our views only as of the date of this press
release and should not be relied upon as representing our views as
of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1
415-937-5400ir@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeValerie Enes+1
408-497-8568valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024